The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2006
DOI: 10.1136/jcp.2004.023358
|View full text |Cite
|
Sign up to set email alerts
|

Peritoneal mucinous cystadenocarcinoma of probable urachal origin: a challenging diagnosis

Abstract: This report describes the case of a mucinous cystadenocarcinoma of probable urachal origin that presented with mass effect, precipitating deep venous thrombosis and pulmonary embolism. The patient presented with acute symptoms of leg swelling, pain and dyspnoea, and a vague awareness of lower abdominal distension. Computer tomography showed a cystic mass closely related to the anterior abdominal wall and the superior aspect of the bladder. A 1500 cm3cyst adherent to the dome of the urinary bladder was resected… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2008
2008
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 9 publications
(10 reference statements)
0
7
0
Order By: Relevance
“…Reported primary sources for this malignancy include ovary, bowel and pancreas, [1][2][3] but may also include bladder and urachal remnants. 4 The retroperitoneum is an extremely rare location for this cancer to develop, with Thamboo and colleagues 5 and Green and colleagues 6 having reported the only other 2 cases of retroperitoneal mucinous cystadenocarcinoma in a male.…”
Section: Discussionmentioning
confidence: 99%
“…Reported primary sources for this malignancy include ovary, bowel and pancreas, [1][2][3] but may also include bladder and urachal remnants. 4 The retroperitoneum is an extremely rare location for this cancer to develop, with Thamboo and colleagues 5 and Green and colleagues 6 having reported the only other 2 cases of retroperitoneal mucinous cystadenocarcinoma in a male.…”
Section: Discussionmentioning
confidence: 99%
“…[13] Gore and associates described the clinico-pathological criteria to label urachal adenocarcinoma and distinguish it from bladder or metastatic process: (1) sharp demarcation between tumor and an intact, normal surface urothelium, (2) the absence of cystitis cystica or glandularis, and (3) tumor growth in the bladder with extension in the bladder dome or anterior wall. [2] Immunohistochemically, cytokeratin 20 is expressed in more than 80% of urachal adenocarcinoma and tumor cells may express CEA and CA 19-9 with raised serum levels as tumor markers. [12] In 1901, Frankel reported a case in which PMP was found associated with a ruptured mucocele of the appendix.…”
Section: Discussionmentioning
confidence: 99%
“…[2] Immunohistochemically, cytokeratin 20 is expressed in more than 80% of urachal adenocarcinoma and tumor cells may express CEA and CA 19-9 with raised serum levels as tumor markers. [12] In 1901, Frankel reported a case in which PMP was found associated with a ruptured mucocele of the appendix. [3] The PMP is a rare and indolent disease that preferentially affects women between 50 and 70 years and appendix is now established as the primary source of most PMPs, which may then spread to other sites like ovaries.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations